Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
C 137.32 4.29% 5.65
BGNE closed up 4.29 percent on Friday, May 20, 2022, on 76 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 4.29%
NR7 Range Contraction 4.29%
Inside Day Range Contraction 4.29%
Wide Bands Range Expansion 4.29%
Multiple of Ten Bullish Other 4.75%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 2 days ago
Outside Day 2 days ago
Fell Below Previous Day's Low 2 days ago
Down 1% 2 days ago
Reversed from Up 2 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BeiGene, Ltd. Description

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibody Lymphoma Monoclonal Antibodies Oncogenes Protein Kinase Kras Bruton's Tyrosine Kinase Ras Subfamily Recombination Rp1

Is BGNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 426.56
52 Week Low 120.0
Average Volume 342,252
200-Day Moving Average 267.11
50-Day Moving Average 170.46
20-Day Moving Average 146.13
10-Day Moving Average 133.12
Average True Range 12.32
RSI 41.86
ADX 28.62
+DI 18.65
-DI 31.44
Chandelier Exit (Long, 3 ATRs) 141.21
Chandelier Exit (Short, 3 ATRs) 156.95
Upper Bollinger Bands 174.43
Lower Bollinger Band 117.83
Percent B (%b) 0.34
BandWidth 38.73
MACD Line -12.33
MACD Signal Line -12.70
MACD Histogram 0.3718
Fundamentals Value
Market Cap 12.49 Billion
Num Shares 90.9 Million
EPS -11.29
Price-to-Earnings (P/E) Ratio -12.17
Price-to-Sales 63.24
Price-to-Book 4.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 152.54
Resistance 3 (R3) 151.56 145.50 150.00
Resistance 2 (R2) 145.50 141.63 146.00 149.16
Resistance 1 (R1) 141.41 139.23 138.39 142.39 148.31
Pivot Point 135.36 135.36 133.84 135.85 135.36
Support 1 (S1) 131.27 131.48 128.24 132.25 126.33
Support 2 (S2) 125.21 129.09 125.70 125.48
Support 3 (S3) 121.12 125.21 124.64
Support 4 (S4) 122.10